Beam Therapeutics Sees Stock Surge Following FDA Orphan Drug Approval
Beam Therapeutics Inc. has seen a 5.7% increase in stock value following the FDA’s approval of orphan drug status for one of its gene-editing therapies.
2 minutes to read
BEAM THERAPEUTICS INC
Beam Therapeutics Soars on FDA Orphan Drug Status and Strong Earnings Report
Beam Therapeutics Inc. sees a surge in stock value after the FDA grants orphan drug status to one of its gene-editing therapies, a move that could streamline the path to market for groundbreaking treatments.
3 minutes to read
Beam Therapeutics Faces Financial Hurdles, Eyes Long-Term Growth with DNA Editing Innovations
Beam Therapeutics Inc. reported a larger-than-expected loss in its first-quarter 2025 financial results, but remains committed to advancing its clinical programs and achieving long-term stability.
2 minutes to read
Beam Therapeutics Reports Higher Q1 Loss, Projects Long-Term Stability Amid R&D Advances
Beam Therapeutics Inc. reported a $109.27 million loss in Q1 2025, exceeding last year’s figures and analyst expectations, but projects financial stability through 2028.
2 minutes to read